February 2020 Vol 13, Special Issue

Conference Highlights ASH

Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019

Multiple Myeloma

Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma

Emerging Therapies

Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy

Leukemia, Value-Based Care

First National Study: Geographic Socioeconomic Disparities Mirror Substantial Gaps in Survival in Children with AML

Drug Updates, FDA Approvals

Tazverik First FDA-Approved Drug for Advanced Epithelioid Sarcoma Ineligible for Resection

Drug Updates, FDA Approvals

Ayvakit First Targeted Therapy Approved for Gastrointestinal Stromal Tumors with PDGFRA Mutation

Breast Cancer, Drug Updates, FDA Approvals

Enhertu, a Dual-Targeted Therapy, Approved for Metastatic HER2-Positive Breast Cancer

Drug Updates, FDA Approvals

Padcev, a Novel Targeted Therapy, FDA Approved for Advanced or Metastatic Urothelial Cancer

Drug Updates, FDA Approvals

Keytruda Indicated for BCG-Unresponsive High-Risk, Non–Muscle Invasive Bladder Cancer

Drug Updates, FDA Approvals, Pancreatic Cancer

Lynparza Indicated for Maintenance Treatment of Metastatic Pancreatic Cancer with BRCA Mutation

1
2
3

Page 1 of 3
Results 1 - 10 of 23

Copyright © Engage Healthcare Communications, LLC. All rights reserved.